Grifols (GIKLY) Net Income towards Common Stockholders (2010 - 2019)

Grifols (GIKLY) posted Net Income towards Common Stockholders of $330.1 million for Q1 2020, down 55.46% quarter-over-quarter from $741.2 million in Q4 2019, and up 69.41% year-on-year from $194.8 million in Q2 2019.

Grifols (GIKLY) Net Income towards Common Stockholders (2010 - 2019) Analysis & Trends

Grifols (GIKLY) has reported Net Income towards Common Stockholders for 11 consecutive years, with $330.1 million the latest figure, recorded in Q1 2020.

  • Net Income towards Common Stockholders for Q1 2020 came in at $330.1 million, up 69.41% year-over-year; the trailing twelve-month figure through Dec 2021 was $330.1 million (down 69.19% YoY), and the FY2025 annual result was $467.9 million, up 178.92% from the prior year.
  • Net Income towards Common Stockholders was $330.1 million for Q1 2020 at Grifols, down from $741.2 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $882.3 million in Q4 2017 and troughed at $136.4 million in Q2 2016.
  • Average Net Income towards Common Stockholders over 5 years is $358.1 million, with a median of $247.9 million recorded in 2017.
  • Year-over-year, Net Income towards Common Stockholders soared 92655.59% in 2016 and plunged 35.0% in 2017.
  • Over 5 years, Net Income towards Common Stockholders stood at $150.5 million in 2016, then surged by 486.37% to $882.3 million in 2017, then decreased by 9.06% to $802.4 million in 2018, then slipped by 7.63% to $741.2 million in 2019, then sank by 55.46% to $330.1 million in 2020.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $330.1 million in Q1 2020, $741.2 million in Q4 2019, and $194.8 million in Q1 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 7.40 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 5.24 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 697.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 47.33 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -4.21 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 2.02 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -13.00 Mn
9 Novartis Ag 113.45 Bn 113.67 Bn - 1.65
10 Grifols - - - -

Historic Data

Download Data
DateValue
Dec 31, 2019 741.18 Mn
Dec 31, 2018 802.38 Mn
Dec 31, 2017 882.31 Mn
Dec 31, 2016 150.47 Mn
Dec 31, 2015 143.08 Mn
Sep 30, 2015 155.84 Mn
Jun 30, 2015 147,000.37
Dec 31, 2014 -423.67 Mn
Sep 30, 2014 151.51 Mn
Jun 30, 2014 142,485.34
Mar 31, 2014 165.78 Mn
Dec 31, 2013 -363.46 Mn
Sep 30, 2013 111.62 Mn
Jun 30, 2013 119.87 Mn
Mar 31, 2013 120.15 Mn
Dec 31, 2012 -255.93 Mn
Sep 30, 2012 79.85 Mn
Jun 30, 2012 84.76 Mn
Mar 31, 2012 88.55 Mn
Dec 31, 2011 -59.02 Mn